Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viagraf is a pharmaceutical medication containing sildenafil citrate, primarily indicated for the treatment of erectile dysfunction (ED). It belongs to the class of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitors. The mechanism of action involves the inhibition of the PDE5 enzyme in the corpus cavernosum of the penis, which prevents the degradation of cGMP. Increased levels of cGMP lead to smooth muscle relaxation and enhanced blood flow into the penile tissues during sexual stimulation, thereby facilitating an erection. Viagraf is developed and manufactured by Global Napi Pharmaceuticals and is commonly marketed in regional markets such as Egypt as a generic alternative to the original brand, Viagra.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Viagraf.